Abstract. Sepsis is a systemic inflammatory response syndrome caused by infection of bacteria, fungi and/or viruses in clinical patients. It is known that inflammatory cytokine levels have an essential role in the progression of sepsis. The present study investigated the role of inflammatory markers in human peripheral blood mononuclear cells (hPBMCs) of patients with sepsis at an intensive care unit. In addition, the plasma levels of inflammatory cytokines were compared between sepsis patients and healthy individuals. The results demonstrated that the serum levels of interleukin-1, -17 and -6, as well as tumor necrosis factor-α, were upregulated in sepsis patients. The serum levels of high mobility group box 1 and C-reactive protein were increased in sepsis patients compared with those in healthy individuals. The expression levels of nuclear factor-κB-p65 and its inhibitor IκBα, as well as the ratio of CD25 + cells, and the levels of neutrophil gelatinase-associated lipocalin and peptidoglycan recognition protein were higher in hPBMCs in sepsis patients compared with those in healthy individuals. It was also indicated that balance of T helper type 1/2 cytokines was also disturbed in patients with sepsis compared with that in healthy individuals. In conclusion, these results indicated that inflammation is involved in the progression of sepsis by interfering with the expression of various molecules, suggesting a potential therapeutic strategy for the treatment of sepsis patients.
Introduction
Sepsis is a systemic inflammatory response syndrome caused by infection with bacteria, fungi and/or viruses (1, 2) . Although sepsis is caused by infection, the development of sepsis is based on a series of inflammatory responses and the pathological processes associated with them (3, 4) . Biomarkers in serum may be used to diagnose for patients with sepsis (5) . Although numerous strategies have been explored for the treatment of sepsis, affected patients still have an increased risk of mortality (6, 7) . A previous study also demonstrated that a reduction of inflammatory factors significantly improved metabolic parameters that are beneficial for survival in septic rats (8) . In addition, distinct shock phenotypes were apparent, and the effect of early resuscitation according to protocols has been examined in selected cohorts of patients with septic shock (9) .
Sepsis is associated with a complex systemic inflammation, which may lead to immune dysfunction, abnormal coagulant function and tissue damage caused by infection with various pathogenic microorganisms, as well as by toxins (10, 11) . Various studies suggested that sepsis is closely associated with the pathological processes of inflammation (12, 13) , which may require further elucidation. Sepsis is thought to result from acute and postponed inflammatory responses via the increasing of plasma inflammatory cytokines levels and leukocytes in affected patients (14, 15) . A previous study also has indicated the role of inflammatory responses in the progression of sepsis, suggesting inhibition of inflammatory responses may contribute to the alleviation of jejunum injury in rats with sepsis (16) . In addition, a randomized controlled trial has suggested that reducing lipopolysaccharide-triggered inflammation is beneficial for the treatment of human sepsis by downregulation of the plasma levels of interleukin (IL)-6, IL-8 and tumor necrosis factor (TNF)-α (17). Furthermore, Kaplan et al (18) have indicated that reducing inflammation through inhibition of nuclear factor (NF)-κB is an efficient strategy for the treatment of sepsis patients. These studies suggest that inflammation is associated with the progression of pathology of sepsis and may be potential target for its treatment.
Systemic inflammatory response syndrome is thought to be associated with the progression of sepsis patients (19) . Therefore, detection of markers of the inflammatory response may be considered as a way to evaluate the prognosis of sepsis. The purpose of the present study was to investigate the expression levels of inflammatory cytokines between patients with sepsis and healthy individuals. The importance of inflammatory responses in the evaluation of patients with sepsis was also investigated. Human peripheral blood monouclear cells (hPBMCs) were separated by density gradient centrifugation using 10 ml of 0.01% cesium chloride at 4,000 x g for 30 min at 4˚C. Total RNA was extracted from hPBMCs cells using RNAzol (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), and RNase-free DNase was applied to digest total DNA at 37˚C for 15 min. The RNeasy kit was then used to purify RNA to adjust its concentration to 1 µg/µl. A total of 2 µg RNA was used as the template to synthetize complementary (c)DNA by reacting with reverse transcriptase at 37˚C for 120 min, at 99˚C for 4 min and at 4˚C for 3 min using the High Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocol. Subsequently, PCR was employed to amplify the cDNA of neutrophil gelatinase-associated lipocalin (NGAL), peptidoglycan recognition protein (PRP), cluster of differentiation (CD)64, procalcitonin (PCT), NF-κB-p65, inhibitor of NF-κB (IκBα), IL-1, IL-17, TNF-α and IL-6 using the primers listed in Table I to determine the transcription level of the respective mRNA. PCR amplification had preliminary denaturation at 95˚C for 1 min, followed by 40 cycles of 95˚C for 30 sec, 58˚C for 30 sec and 72˚C for 10 min. The reaction volume was a total of 20 µl containing 50 ng genomic cDNA, 200 µM dNTPs, 200 µM primers, and Taq DNA polymerase and SYBR-Green (both 2.5 U; Thermo Fisher Scientific, Inc.). β-Actin was used as the housekeeping gene for the internal control group. Eventually, agarose electrophoresis with 1% ethidium bromide was adopted to check PCR-amplified products. Changes in relative mRNA expression were calculated by the 2 -ΔΔCq method (20) . The results are expressed as the fold change compared with the control.
Materials and methods

Ethical
ELISA. Plasma samples were immediately prepared from peripheral venous blood by centrifugation (2,000 x g at 4˚C for 10 min). Serum levels of TNF-α (cat. no. MBS6080), IL-1 (cat. no. MBS700340), IL-6 (cat. no. MBS3205), high mobility group box 1 (HMGB1; cat. no. MBS4108) and C-reactive protein (CRP; cat. no. MBS910284; all from Thermo Fisher Scientific, Inc.) were analyzed in patients with sepsis using ELISA kits according to the manufacturer's protocols. The balance of T-helper cell type 1 (Th1)/Th2 cytokines was analysed using Th1/Th2 Human Th1/Th2 (7 plex) Multiplex Immunoassay kit (cat. no. ab213389; Abcam, Cambridge, UK) according to the manufacturer's protocol. The serum levels of these cytokines were measured with a micro-plate reader at 570 nm.
Flow cytometry. From the peripheral blood drawn from the patients with sepsis, total leukocytes were extracted using a Human Leukocyte Extract Kit (Invitrogen; Thermo Fisher Scientific, Inc.). The proportion of lymphocytes, granulocytes and mononuclear cells among total leukocytes in the plasma was analyzed by flow cytometry as previously described (21) . The hPBMCs was also incubated with fluorescein isothiocyanate-labelled CD25 (1:1,000; cat. no. ab210335; Abcam) for 12 h at 4˚C. The proportion of hPBMCs presenting the activation marker CD25 was analysed by flow cytometry using FCS Express™ 4 IVD (De Novo Software, Glendale, CA, USA).
Statistical analysis. Statistical analysis was performed using SPSS 19.0 software (IBM Corp., Armonk, NY, USA) and Excel (version 2010; Microsoft Corp., Redmond, WA, USA). All values are expressed as the mean ± standard error of the mean of triplicate experiments. Differences between groups were analyzed using Student's two-tailed t-test. P<0.05 was considered to indicate a statistically significant difference.
Results
Characteristics of patients with sepsis.
A total of 122 patients with sepsis and 106 healthy individuals were recruited for the present clinical analysis. The ratios of males and females among the groups of sepsis patients and healthy individuals were approximately equal. The mean age was 45.4±18.3 and 47.2±18.6 years in sepsis patients and healthy individuals, respectively. The characteristics of patients with sepsis are summarized in Table II . The blood pressure was higher in sepsis patients than that in healthy individuals (130 vs. 106 mm Hg; P<0.01; Fig. 1 ).
Inflammatory cytokines are increased in serum of patients with sepsis at the ICU. Changes of inflammatory cytokines in the serum of patients with sepsis were analyzed. The serum levels of IL-1, IL-17, TNF-α and IL-6 were identified to be upregulated in sepsis patients compared with those in healthy individuals (P<0.01; Fig. 2 ). These results suggest that inflammatory cytokines were obviously upregulated in the serum of patients with sepsis at the ICU.
Analysis of inflammatory cytokine mRNA expression in hPBMCs of patients with sepsis at the ICU.
The gene expression levels of inflammatory cytokines in hPBMCs of patients with sepsis were assessed in the present study. The mRNA expression levels of IL-1 (2.07-fold), IL-17 (1.76-fold), TNF-α (2.46-fold) and IL-6 (1.96-fold) were markedly up-regulated in hPBMCs of patients with sepsis compared with that in healthy individuals (P<0.01; Fig. 3 ). These results suggest that the gene expression levels of inflammatory cytokines are upregulated in hPBMCs of patients with sepsis in an ICU setting.
Analysis of inflammatory cells in serum of patients with sepsis at the ICU.
To explore the role of inflammation in the progression of sepsis, changes in the ratio of inflammatory cells were investigated in serum in patients with sepsis. As presented in Fig. 4 , the percentages of lymphocytes, plasmacytes, neutrophils and monocytes among the total leukocytes were increased in patients with sepsis at the ICU compared Values are expressed as mean ± standard deviation or n. with those in healthy individuals (P<0.01). These results suggest that inflammatory cells are upregulated in serum of patients with sepsis at the ICU.
Analysis of biomarkers of inflammatory cytokines in patients
with sepsis at the ICU. The presentation of biomarkers of inflammatory cytokines on hPBMCs of patients with sepsis at the ICU was then analyzed. The results indicated that the proportion of hPBMCs presenting the activation marker CD25 was significantly increased in sepsis patients compared with that in healthy individuals (9.00 vs. 3.95%; P<0.01; Fig. 5A ).
As presented in Fig. 5B , NGAL and PRP were significantly upregulated in hPBMCs of sepsis patients compared with those from healthy individuals (3.67-and 2.09-fold for NGAL and PRP, respectively). The balance of T-helper cell type 1 (Th1)/Th2 cytokines was decreased in patients with sepsis (2.38 vs. 0.41%; P<0.01; Fig. 5C ). In addition, the serum levels of HMGB1 and C-reactive protein (CRP) were increased in sepsis patients compared with those in healthy individuals (HMGB1, 55.95 vs. 16.88; CRP, 13.80 vs. 4.10; P<0.01; Fig. 5D ). These results suggest that biomarkers of inflammatory cytokines are upregulated in serum of patients with sepsis in an ICU setting.
Analysis of biomarkers of inflammation in hPBMCs of
patients with sepsis at the ICU. The gene expression levels of biomarkers of inflammation in hBPMCs of patients with sepsis at the ICU were then explored. The results indicated that the gene expression levels of NF-κB-p65, IκBα, CD64 and PCT were higher in hPBMCs than those in healthy individuals (NF-κB-p65, 3.79-fold; IκBα, 2.17-fold; CD64, 2.97-fold; PCT, 2.72-fold; P<0.01; Fig. 6 ). These results suggest that the mRNA expression of inflammatory biomarkers in hPBMCs was upregulated in patients with sepsis in an ICU setting.
Discussion
Sepsis can leads to accumulation of bacterial endotoxins, release of inflammatory mediators and immune dysfunction (22, 23) . Inflammatory responses are the major reason leading to mortality of patients with sepsis (24, 25) . The present study analyzed the changes of serum inflammatory cytokines and markers in hPBMCs of patients with sepsis in an ICU setting. The present results indicated that the serum levels of inflammatory cytokines, biomarkers and inflammatory cells were upregulated in patients with sepsis compared with those in healthy individuals. Circulating inflammatory cytokines have been identified as mediators of damage in patients with sepsis (26) . The present study reported the upregulation of the inflammatory cytokines IL-1, IL-17, TNF-α and IL-6 in sepsis patients compared with those in healthy individuals. Cross (27) suggested that targeting IL-1/IL-17A may improve therapeutic outcomes for patients with sepsis. Studies have also demonstrated that the serum levels of the cytokines TNF-α and IL-6 were increased and that the TNF-α-308 G/A polymorphism is associated with post-operative sepsis (28) (29) (30) (31) . The present study indicated that the serum levels of inflammatory cytokines and the gene expression levels of IL-1, IL-17, TNF-α and IL-6 in hPBMCs were upregulated in patients with sepsis at the ICU compared with those in healthy individuals. Of note, the serum concentrations of inflammatory cells, including lymphocytes, plasmacytes, neutrophil and monocytes among the leukocytes, were markedly increased in patients with sepsis compared with those in healthy individuals.
HMGB1 is regarded as a predicator of organ dysfunction in patients with severe sepsis (32, 33) . The role of CRP in sepsis has been reported in multidisciplinary studies on patients in the ICU setting (34, 35) . The present study reported that the serum levels of HMGB1 and CRP were significantly increased in sepsis patients compared with those in healthy individuals. Wang et al (36) reported that attenuating CD4 + CD25
+ T-regulatory cells ameliorated burn sepsis. In addition, plasma NGAL has been used to diagnose acute kidney injury in patients with systemic inflammatory disease and sepsis (37) . Furthermore, peptidoglycan recognition protein is associated with inflammation in patients with bacterial infection (38, 39) . The present results suggest that biomarkers of inflammatory cytokines are upregulated in serum of patients with sepsis at the ICU compared with that in healthy individuals.
Studies have indicated that inhibition of NF-κB activation is beneficial for the treatment of experimental sepsis (40, 41) . Song et al (42) reported that benzenediamine derivate FC-98 exhibited anti-inflammatory efficacy against sepsis injury in mice via suppression of c-Jun N-terminal kinase, NF-κB and interferon regulatory transcription factor 3 signaling pathways. The present study indicated that NF-κB gene expression levels are higher in hPBMCs of patients with sepsis than those in healthy individuals, which may provide a potential target for the treatment of sepsis.
In conclusion, the present study indicated an upregulation of inflammatory cytokines in the serum of patients with sepsis. These results suggest that inflammatory cytokines are potential targets for the treatment of sepsis patients. It was also indicated that the balance of Th1/Th2 cytokines was decreased in patients with sepsis in an ICU setting compared with that in healthy individuals, which may provide a potential diagnostic tool for patients with sepsis.
